ReviewPLoS pathogens2023
Environmental reservoirs of the drug-resistant pathogenic yeast Candida auris.
Review in PLoS pathogens, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 65 citations in OpenAlex.
- Effect of intrapartum azithromycin on early childhood gut mycobiota development: post hoc analysis of a double-blind randomized trial.Nature communications · 2025Trial
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- Diversity, antifungal susceptibility, and biofilm formation of fish-associated yeasts from freshwater and marine fish.Veterinary research communications · 2026Article
- Wastewater surveillance as an early warning system for fungal pathogens.PLoS pathogens · 2026Article
- Environmental Detection of Candidozyma (Candida) auris in Surface Waters of the Gediz Delta, a Critical Coastal Wetland in Türkiye: Expanding One Health Surveillance Perspective.Mycopathologia · 2026Article
- Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.npj antimicrobials and resistance · 2026Review
- Post-brumation yeast mycobiota in Vipera berus (European adder): clinically relevant Candida parapsilosis oral dominance and diverse fecal communities compared with warmer-region snakes.Veterinary research communications · 2026Article
- The dual role of azoles: lifesaving antifungals and drivers of resistance - a One Health perspective.Nature communications · 2026Review
- Article
- UnderstandingJournal of medical microbiology · 2026Review
- Breaking the Chain of Infection: A Systematic Review of Environmental Decontamination ofJournal of fungi (Basel, Switzerland) · 2026Review
- Distinct properties of human pathogenicmSystems · 2026Article
- Article
- Accumulation of Trehalose 6-Phosphate in Candidozyma auris results in Decreased Echinocandin Resistance and Tolerance.Nature communications · 2025Article
- Article
- Environmental Yeast Abundance and Diversity Assessment in Recreation Areas of Bangkok, Thailand.Environmental microbiology reports · 2025Article
- Brown locusts, Locustana pardalina, host fluconazole-resistant Candidozyma (Candida) auris, closely related to Clade III clinical strains.Medical mycology · 2025Article
- Discrimination of Clinical and Food-DerivedPathogens (Basel, Switzerland) · 2025Article
- Thermotolerance, virulence, and drug resistance of human pathogenic Candida species colonising plastic pollution in aquatic ecosystems.Environmental science and pollution research international · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candia auris is an emerging human pathogenic yeast; yet, despite phenotypic attributes and genomic evidence suggesting that it probably emerged from a natural reservoir, we know nothing about the environmental phase of its life cycle and the transmission pathways associated with it. The thermotolerant characteristics of C. auris have been hypothesised to be an environmental adaptation to increasing temperatures due to global warming (which may have facilitated its ability to tolerate the mammalian thermal barrier that is considered a protective strategy for humans against colonisation by environmental fungi with pathogenic potential). Thus, C. auris may be the first human pathogenic fungus to have emerged as a result of climate change. In addition, the release of antifungal chemicals, such as azoles, into the environment (from both pharmaceutical and agricultural sources) is likely to be responsible for the environmental enrichment of resistant strains of C. auris; however, the survival and dissemination of C. auris in the natural environment is poorly understood. In this paper, we critically review the possible pathways through which C. auris can be introduced into the environment and evaluate the environmental characteristics that can influence its persistence and transmission in natural environments. Identifying potential environmental niches and reservoirs of C. auris and understanding its emergence against a backdrop of climate change and environmental pollution will be crucial for the development of effective epidemiological and environmental management responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.